drugset
drugset / Trial / NCT03393468

Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults

NCT03393468 ↗

Phase 1 Completed 16 enrolled National Institute of Allergy and Infectious Diseases (NIAID)
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the pharmacokinetics of dapivirine gel administered rectally to HIV-1 seronegative adults.

Timeline

Start
2018-05-10
Primary completion
2018-12-03
Completion
2018-12-03

Drugs

EvaluationDrugModalityDoseRoute
Subject dapivirine Small molecule 2.5 g Rectal
Subject dapivirine Small molecule 10 g Rectal

Indications

HIV infectious disease